Sign In
Buy VCYT
$46.32
-13.46 (-22.52%)
At Close: Jul 31, 2026
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
12:20pm, Monday, 25'th May 2026
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
10:51am, Monday, 25'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
08:00am, Friday, 22'nd May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 20
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
06:00pm, Thursday, 21'st May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer.
Veracyte to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 19'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Grow
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term
10:45am, Monday, 18'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
09:00am, Friday, 15'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BladderCancer--Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer.
Veracyte Inc (VCYT) Shares Fall 3.3% -- What GF Score of 82 Tells Investors
08:19pm, Wednesday, 13'th May 2026
On May 13, 2026, Veracyte Inc (VCYT) shares fell 3.3%, bringing the current price to $38.26. The stock has experienced a 52-week range of $22.61 to $50.71, show
Why Veracyte Stock Is Skyrocketing Higher This Week
12:51am, Friday, 08'th May 2026
Veracyte grew revenue by 21% in Q1 and saw earnings per share quadruple from last year, as margins ballooned. Sales for the company's main prostate and thyroid cancer-detecting tests continue to grow
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors
10:31am, Thursday, 07'th May 2026
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 200-day moving average, suggesting a long-term bull
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
10:51pm, Tuesday, 05'th May 2026
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates
09:36pm, Tuesday, 05'th May 2026
Veracyte (VCYT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.31 per share a year ago.
Veracyte Announces First Quarter 2026 Financial Results
04:05pm, Tuesday, 05'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. “We h
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet
10:55am, Tuesday, 05'th May 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 39.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the posit
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #AUA26--Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
